Objective: To analyze the clinical effects of different doses of sacubitril valsartan sodium in the treatment of chronic heart failure. Methods: 144 patients with chronic heart failure in our hospital were selected from February 2024 to February 2025, and were divided into low-dose group, middle-dose group and high-dose group according to the dose, with 48 cases in each group. All patients were treated with sacubitril valsartan sodium, and the three groups were compared in terms of efficacy, cardiac function, stress indexes [superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA)], inflammatory factors [interleukin-6 (IL-6), ultrasensitive C-reactive protein (hs-CRP), and tumor necrosis factor-alpha (TNF-alpha)] levels, 6min walking distance (6MWT ), heart failure quality of life scale (MLHFQ), and adverse reactions. Results: Compared with 62.50% in the low-dose group and 75.00% in the medium-dose group, the therapeutic efficiency of the high-dose group was 91.67% (P < 0.05); after the administration of medication, the levels of LVEF, LVEDD, and LVESD in the high-dose group were superior to those in the low-dose group and the medium-dose group, the levels of SOD, NO, and MDA in the high-dose group were superior to those in the low-dose group and the medium-dose group, and the levels of IL-6, hs- CRP, TNF-α levels were better than those in the low-dose group and medium-dose group, and 6MWT and MLHFQ scores were better than those in the low-dose group and medium-dose group in the high-dose group (P < 0.05); the incidence rate of adverse reactions in the high-dose group was 12.50% compared with that in the low-dose group (4.17%) and the medium-dose group (8.33%) (P > 0.05). Conclusion: Chronic heart failure patients in the conventional treatment based on the supplementation of high-dose sarcoplasmic retroviral sartan sodium, can effectively improve the patient"s cardiac function, the clinical effect is more reliable, is conducive to the patient to obtain a better quality of life, in addition to the patient"s therapeutic safety can provide security, has the value of clinical popularization of the use of the value.